IOVA Iovance Biotherapeutics Inc

$IOVA In these dark days, I thought it useful to compare IOVA and TGTX. Both have game changing treatments for extremely serious medical conditions (solid tumors and MS). Both have seen exceptional revenue growth - and wild sp swings - since FDA approval. Following FDA approval in Dec 2022, TGTX spiked from 7.50 to 34. Then crashed to 6.75 in October of 2023. Since then, TGTX's sp has tracked increased revenue - with extreme volatility along the way. TGTX did $310 million in revenue in 2024, $600 million in 2025 and projects $900+ million in 2026. Even after todays bloodbath, TGTX is now at $58: an 850% return since its Oct 2023 lows. We are all familiar with IOVA's similar sp volatility since its Feb 2024 approval. Nonetheless, it is projecting roughly $450 million in revenue in 2026, putting it roughly 5-6 qs behind TGTX in revenue growth. Needless to say, If IOVA's revenue and sp track TGTX's in the coming years, we will all be naming our kids Fred - even the girls. Patience.

$IOVA I'm certainly not a soothsayer or diviner by any means but, regardless of the recent volatility (WHICH COMES WITH THE TERRITORY FOR BIOTECHS KIDS), objectively the underlying financials and overall cashflow trajectory here is quite possibly the best for any biotech I've ever invested in which is deeply encouraging for me personally. It's a marathon, not a sprint...

$IOVA already almost profitable with melons alone, upcoming sarcoma data looking very positive, lung cancer indication doesn’t cure everyone but cures or positively affects a large subset. Cost decreasing, revenue increasing. Best biotech opportunity on market today

$IOVA While the market gets hammered, I added another 10,000 shares today. After 30 plus years in this game, I’m not getting shaken out by a dermatologist playing Wall Street analyst or the usual parade of bearish munchkins. I’m invested alongside a proven beast who’s made a fortune backing big opportunities. While they’re busy making noise, I’m busy building my position. I believe these prices will look like a gift 12 months from now, with the mid $20S or higher firmly in my sights. They can keep the opinions. I’ll follow the conviction and the big capital.

$IOVA You just have to laugh about Iovance’s ER being the same day as the largest single day $ drop in U.S. stock market history 😂 ER was absolutely solid.

$IOVA very bullish 2027 - Profitable in 2027, - Revenues of $ 1 billion, - Cash of at least $400mm, - At least 175 treatment centers by year end 2027, - Major takeover target in the $45-$60 range!

$IOVA The best quarter ever. Projected to turn a profit on melonoma alone. Sarcoma fast tracked. Lung is looking like a monster once it is approved. Yet we have a 50% haircut from last week. Just keep on buying and averaging down/up and let us see how the bones roll.

$IOVA Real people. Real disease. Real hope. Real cures. Fourteen years after TIL therapy, some patients are still celebrating anniversaries. Others are just starting their journey day one in the hospital, holding hands, ready to fight. A year later, clean scans. A second clean PET. Messages of “You’ve got this” from people who’ve walked the same path. This is what TIL therapy looks like beyond the numbers: patients who were told their options were limited, now marking years of life they weren’t sure they’d have. One treatment. One shot. Lives continuing. The data shows consistency. The patients show what’s possible. The numbers matter. The people matter more.

$IOVA Thats still a Huge Win !!!!!! ----> My current conclusion: no competitor has better published results in this exact subgroup. The US biomarker TAM is probably around 10,000–12,000 patients annually, but lifileucel’s realistically treatable population is more likely 3,500–6,600

$IOVA Lifileucel ORR consistency + durability across expanding datasets. As patient numbers grew in melanoma (C-144-01), the objective response rate stayed remarkably stable (29–36% range, settling at 31% by independent review). Median duration of response in the full pooled analysis reached 36.5 months. Real world experience has been even higher, particularly when used earlier. The same pattern is holding in non squamous mNSCLC (IOV-LUN-202): 25.6% (n=39) 24.6% (n=69). Mdor not reached Consistent response rates and meaningful durability as datasets mature are critical indicators of a therapy’s reliability. When efficacy metrics remain stable as patient numbers grow rather than fluctuating or declining. It strengthens confidence that the observed activity is real and reproducible. This pattern of consistency across sequential cohorts has been a key factor in the approval of lifileucel in melanoma and supports the likelihood of future regulatory approvals in additional indications

$IOVA Thanks everyone who joined in on this conversation. Your input helps to refine some of my thinking on what's ahead. I know we lost a few of our fellow longs recently, who got knocked out, scared away, or just simply frustrated and angry with how challenging biotech investing can be, especially when the share price doesn't match the perceived value, and big money can manipulate the price at times. Fundamentals typically do win out in the end, but time is part of that equation. I'll be here for a good long time based on my expectation that Iovance has a great future ahead for years and maybe even decades to come, assuming they continue to go it alone. I'll take a little off the table at various points, for no other reason than to spoil the grandkids, but I'm in no hurry to walk away unless the choice is not mine and some BP decides to belly up to the bar and pay the price to buy this company. For the record, it'll need to be a very big number... $20 B, $30 B, $40 B? GL longs.

$IOVA I'm hanging out at the legion and my old neighbor is here. We were talking about a family member of mine who passed form cancer in 2012. The convo got into how so much progress has been made and I mentioned iovance. He looked at me with a raised eyebrow and said I heard of that treatment....it was on the news recently. He's not an investor. Awareness is spreading 😁 we got a gem here.

$IOVA Will 2027 be profitable? Can some of you please give me your back of the napkin analyses of 2027's financials? Expenses are far more controlled, revenue is increasing significantly with 2027 possibly exceeding $600 million, and margins are improving. It seems that profitability should be in sight. Am I missing something, or am I correct in thinking we'll cross into profits over the next 12-14 months? TIA to any of our board's number crunchers. GL

$IOVA I've alway liked the SAS motto, "who dares wins". Just bought 63,500 shares at 7.72. LFG

$IOVA TIL therapy is delivering consistent, reproducible results across solid tumors and earlier use is looking even better. In the small but striking UPS/DDLPS pilot, lifileucel (Amtagvi) produced a confirmed 55.6% ORR in heavily pretreated patients, with durable ongoing responses. This fits the pattern we’ve seen in larger datasets response rates hold steady as patient numbers grow (melanoma ~31%, NSCLC ~25% in post-ICI settings), while durability remains a standout feature. Even more encouraging frontline combinations are showing higher response rates (e.g., 62.5% ORR + 29% CR rate with lifileucel + pembrolizumab in melanoma). The platform appears to work best when used earlier, before multiple lines of therapy have reduced the quality of the TIL product and the patient’s immune fitness. With SARATOGA now enrolling in second line UPS and DDLPS, and broader frontline efforts underway, the case for bringing TIL therapy forward in the treatment sequence continues to strengthen.

$IOVA In the face of today’s total market drubbing, keep in mind: IOVA delivered a 2nd straight RECORD quarter! Absolutely NOTHING bad on that call - NADA! So you know what you own, let me summarize: ✅Tot Rev $121.5M in Q3 - up 80% YOY & 22% sequentially. U.S. Amtagvi $101.6M (+77% YoY, +12% QoQ). Global Proleukin $19.9M. ✅Gross margin ~60%, a record for the 2nd straight Q ✅Net loss $22.3M, or just $0.05 a share, vs $91.3M 1 year ago. Cash of $382.3M - expected to fund operations well into 2029. ✅new CMO, Noah Berkowitz — made his 1st appearance today & used it to lay out a biomarker-driven pipeline strategy. 🔥And that pipeline is the REAL story here (discussed : NSCLC 24.6% ORR w an sBLA planned for 2027, a 59.1% biomarker-selected subgroup, sarcoma 55.6% ORR, & a frontline Mel Phase 3 that also serves as the confirmatory trial for today’s approval.🔥 ✅Guidance reaffirmed for 2026 & per Fred, “the maintenance issue is gone, and the company expects sequential growth.” LFG!!

$IOVA we are not alone along with every other analyst screaming buy after earnings and pipeline updates....Schwab report out this morning launched us, yet again, up their rating system to "B" outperform/buy at 18/100 rating. This jump came after their recognition of growth in Thursday's ER. For anyone new - we were sitting at "F" 97-100 sell 6 months ago. As I always note, taken with a grain of salt, but positive feedback nonetheless. While the pullback was disheartening, especially while seeing some low float (and anemic low/falsely value portraying volume) names from the past still haunting us with what appears market positivity.....account values aside, comparisons to others in the sector aside, they are exexcuting exactly how they should at Iovance.

$IOVA What an incredible ER call yesterday. Business is firing on all cylinders and Noah is a stud! Added more today like ive done every friday for the last 2+ years. Wishing all longs a peaceful and restful weekend. Congrats on accumulating a gem!!💎

$IOVA Set a calendar reminder. $50 end of 2027. Come back and comment here. Perhaps a once in a lifetime opportunity. Have a nice weekend, bulls.

$IOVA Late this week Iovance added two more authorized treatment centers: - Sanford Medical Center, Fargo, North Dakota - UCLA Santa Monica Medical Center, Santa Monica, CA There are now 107 ATC’s in the USA. They seem to be well ahead of schedule to attain their goal of 110 by the end of the year.